Cantor Fitzgerald Raises Eupraxia Pharmaceuticals (NASDAQ:EPRX) Price Target to $19.00

Eupraxia Pharmaceuticals (NASDAQ:EPRX) had its price objective boosted by equities research analysts at Cantor Fitzgerald from $11.00 to $19.00 in a research note issued on Thursday,Benzinga reports. The firm currently has an “overweight” rating on the stock. Cantor Fitzgerald’s target price suggests a potential upside of 125.39% from the stock’s previous close.

Other equities analysts have also issued research reports about the company. Weiss Ratings restated a “sell (d-)” rating on shares of Eupraxia Pharmaceuticals in a research note on Wednesday, October 8th. HC Wainwright reaffirmed a “buy” rating and issued a $12.00 price target on shares of Eupraxia Pharmaceuticals in a research note on Friday, January 9th. Wall Street Zen upgraded Eupraxia Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Saturday, December 13th. Lifesci Capital raised shares of Eupraxia Pharmaceuticals to a “strong-buy” rating in a research note on Thursday, December 11th. Finally, Leede Financial upgraded shares of Eupraxia Pharmaceuticals to a “strong-buy” rating in a research report on Wednesday, October 29th. Two research analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Buy” and an average target price of $14.33.

Eupraxia Pharmaceuticals Trading Up 1.4%

Shares of EPRX stock opened at $8.43 on Thursday. Eupraxia Pharmaceuticals has a twelve month low of $2.68 and a twelve month high of $8.74. The stock has a market cap of $303.15 million, a P/E ratio of -9.69 and a beta of 1.21. The stock has a 50 day moving average of $6.73 and a 200 day moving average of $5.96.

Eupraxia Pharmaceuticals (NASDAQ:EPRX) last issued its quarterly earnings data on Tuesday, November 4th. The company reported ($0.19) EPS for the quarter, topping analysts’ consensus estimates of ($0.23) by $0.04. On average, research analysts predict that Eupraxia Pharmaceuticals will post -0.67 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Eupraxia Pharmaceuticals

A number of hedge funds have recently modified their holdings of the company. Quadrature Capital Ltd purchased a new position in Eupraxia Pharmaceuticals during the second quarter worth about $61,000. TCI Wealth Advisors Inc. acquired a new stake in shares of Eupraxia Pharmaceuticals during the third quarter valued at about $65,000. Integrated Wealth Concepts LLC acquired a new stake in Eupraxia Pharmaceuticals in the 3rd quarter valued at approximately $71,000. Bank of America Corp DE raised its position in Eupraxia Pharmaceuticals by 402.4% in the second quarter. Bank of America Corp DE now owns 12,559 shares of the company’s stock valued at $72,000 after purchasing an additional 10,059 shares during the period. Finally, JPMorgan Chase & Co. raised its holdings in shares of Eupraxia Pharmaceuticals by 593.2% in the 2nd quarter. JPMorgan Chase & Co. now owns 18,717 shares of the company’s stock valued at $108,000 after buying an additional 16,017 shares during the period.

About Eupraxia Pharmaceuticals

Eupraxia Pharmaceuticals, Inc (NASDAQ: EPRX) is a clinical-stage biotechnology company dedicated to the discovery and development of novel therapies for autoimmune and inflammatory diseases. The company’s core strategy centers on selectively expanding regulatory T cells (Tregs)—immune cells responsible for maintaining self-tolerance and limiting pathological inflammation—through its proprietary platform. Its lead therapeutic candidate is currently in Phase 1 clinical development in patients with systemic lupus erythematosus.

Based in Seattle, Washington, Eupraxia Pharmaceuticals conducts research and development activities across North America, collaborating with academic institutions and contract research organizations to advance its pipeline.